Diamyd Medical contracts global CRO for Phase III trial with the diabetes vaccine Diamyd®
Diamyd Medical has contracted the global contract research organization (CRO) ICON plc for DIAGNODE-3, a placebo-controlled Phase III precision medicine trial with the diabetes vaccine Diamyd[®]. The trial is designed to confirm the efficacy and safety of Diamyd[®] in individuals recently diagnosed with type 1 diabetes who carry the genetically defined haplotype HLA DR3-DQ2. The trial is expected to begin recruiting patients later this year.“We have gotten to know ICON as a very skilled and committed collaboration partner during the preparation of our Phase III trial,“ says Ulf Hannelius,